These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18367109)

  • 1. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.
    Hajdinjak T
    Urol Oncol; 2008; 26(6):646-51. PubMed ID: 18367109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
    Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
    Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on the diagnosis of urothelial cancer using multi-colour fluorescence in situ hybridization (FISH)--comparative analysis between FISH and cytology].
    Onishi T; Ichikawa T; Igarashi T
    Hinyokika Kiyo; 2008 Apr; 54(4):253-6. PubMed ID: 18516915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
    Asali MG; Kaneti J; Manor E
    Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer.
    Marín-Aguilera M; Mengual L; Ribal MJ; Burset M; Arce Y; Ars E; Oliver A; Villavicencio H; Algaba F; Alcaraz A
    Cancer Genet Cytogenet; 2007 Mar; 173(2):131-5. PubMed ID: 17321328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.
    Huysentruyt CJ; Baldewijns MM; Rüland AM; Tonk RJ; Vervoort PS; Smits KM; van de Beek C; Speel EJ
    Histopathology; 2011 Jun; 58(7):1048-53. PubMed ID: 21707706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Meta-analysis of fluorescence in situ hybridization and cytology for diagnosis of bladder cancer].
    Yang MG; Zhao XK; Hou Y; Xiao N
    Ai Zheng; 2009 Jun; 28(6):655-62. PubMed ID: 19635207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma.
    Halling KC; King W; Sokolova IA; Meyer RG; Burkhardt HM; Halling AC; Cheville JC; Sebo TJ; Ramakumar S; Stewart CS; Pankratz S; O'Kane DJ; Seelig SA; Lieber MM; Jenkins RB
    J Urol; 2000 Nov; 164(5):1768-75. PubMed ID: 11025767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set, statistically derived diagnostic criteria.
    Pajor G; Somogyi L; Melegh B; Alpar D; Kajtar B; Farkas L; Kneif M; Bollmann D; Pajor L; Sule N
    Cytometry A; 2011 May; 79(5):375-82. PubMed ID: 21465665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary fluorescence in situ hybridization assay for detecting urothelial carcinoma in Taiwanese patients.
    Chuang KL; Chuang HC; Ng KF; Chang YH; Wu CT; Chuang CK; Liao SK; Pang ST
    BJU Int; 2010 May; 105(10):1413-6. PubMed ID: 19818076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vysis UroVysion for the detection of urothelial carcinoma.
    Halling KC
    Expert Rev Mol Diagn; 2003 Jul; 3(4):507-19. PubMed ID: 12877389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
    Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
    Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
    Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
    J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice.
    Laudadio J; Keane TE; Reeves HM; Savage SJ; Hoda RS; Lage JM; Wolff DJ
    BJU Int; 2005 Dec; 96(9):1280-5. PubMed ID: 16287445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.
    Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR
    Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
    Bubendorf L; Piaton E
    Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.